Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction: DELIVER trial

Solomon, S. D. et al. (2022) Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction: DELIVER trial. JACC: Heart Failure, 10(3), pp. 184-197. (doi: 10.1016/j.jchf.2021.11.006) (PMID:35241246)

[img] Text
267603.pdf - Published Version
Available under License Creative Commons Attribution.

517kB

Abstract

Objectives: This report describes the baseline clinical profiles and management of DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure) trial participants and how these compare with those in other contemporary heart failure with preserved ejection fraction trials. Background: The DELIVER trial was designed to evaluate the effects of the sodium-glucose cotransporter–2 inhibitor dapagliflozin on cardiovascular death, heart failure (HF) hospitalization, or urgent HF visits in patients with HF with mildly reduced and preserved left ventricular ejection fraction (LVEF). Methods: Adults with symptomatic HF and LVEF >40%, with or without type 2 diabetes mellitus, elevated N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels, and evidence of structural heart disease were randomized to dapagliflozin 10 mg once daily or matching placebo. Results: A total of 6,263 patients were randomized (mean age: 72 ± 10 years; 44% women; 45% type 2 diabetes mellitus; 45% with body mass index ≥30 kg/m2; and 57% with history of atrial fibrillation or flutter). Most participants had New York Heart Association functional class II symptoms (75%). Baseline mean LVEF was 54.2 ± 8.8% and median NT-proBNP of 1,399 pg/mL (IQR: 962 to 2,210 pg/mL) for patients in atrial fibrillation/flutter compared with 716 pg/mL (IQR: 469 to 1,281 pg/mL) in those who were not. Patients in both hospitalized and ambulatory settings were enrolled, including 10% enrolled in-hospital or within 30 days of a hospitalization for HF. Eighteen percent of participants had HF with improved LVEF. Conclusions: DELIVER is the largest and broadest clinical trial of this population to date and enrolled high-risk, well-treated patients with HF with mildly reduced and preserved LVEF. (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure [NCT03619213]).

Item Type:Articles
Keywords:Heart failure with preserved ejection fraction, heart failure with mildly reduced ejection fraction, clinical trials, SGLT-2 inhibitors.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:McMurray, Professor John
Authors: Solomon, S. D., Vaduganathan, M., Claggett, B. L., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S.P., Martinez, F., Shah, S. J., Belohlavek, J., Chiang, C.-E., Willem Borleffs, C. J., Comin-Colet, J., Dobreanu, D., Drozdz, J., Fang, J. C., Alcocer Gamba, M. A., Al Habeeb, W., Han, Y., Cabrera Honorio, J. W., Janssens, S. P., Katova, T., Kitakaze, M., Merkely, B., O'Meara, E., Kerr Saraiva, J. F., Tereschenko, S. N., Thierer, J., Vardeny, O., Verma, S., Vinh, P. N., Wilderäng, U., Zaozerska, N., Lindholm, D., Petersson, M., and McMurray, J. J.V.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:JACC: Heart Failure
Publisher:Elsevier
ISSN:2213-1779
ISSN (Online):2213-1787
Published Online:28 February 2022
Copyright Holders:Copyright © 2022 The Authors
First Published:First published in JACC: Heart Failure 10(3): 184-197
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record